Pulmonary Sarcoidosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Novartis, aTyr Pharma, SarcoMed USA, Actelion, Bellerophon, Corbus Pharma

Pulmonary Sarcoidosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Novartis, aTyr Pharma, SarcoMed USA, Actelion, Bellerophon, Corbus Pharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Pulmonary Sarcoidosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Pulmonary Sarcoidosis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Sarcoidosis Therapeutics Market. 

The report provides a detailed description of the Pulmonary Sarcoidosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Pulmonary Sarcoidosis Pipeline Analysis

Pulmonary Sarcoidosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the key companies that are developing Pulmonary Sarcoidosis therapies.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Sarcoidosis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging Pulmonary Sarcoidosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Pulmonary Sarcoidosis treatment market.

The Report Covers the Emerging Pulmonary Sarcoidosis Therapies Under Different Phases of Clinical Development Like - 

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion

  • Intradermal

  • Intramuscular

  • Intranasal

  • Intravaginal

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

Get a Detailed Overview of the Pulmonary Sarcoidosis Clinical Trial Activities and Regulatory Developments in the domain @ 


Pulmonary Sarcoidosis Therapeutics Analysis 

There are approx. 10+ key companies developing Pulmonary Sarcoidosis therapies. Currently, Corbus Pharmaceuticals is leading the therapeutics market with its Pulmonary Sarcoidosis drug candidates in the most advanced stage of clinical development.

Pulmonary Sarcoidosis Companies in the Therapeutics Market Include:

  • Novartis

  • aTyr Pharma

  • Relief Therapeutics

  • AI Therapeutics

  • SarcoMed USA

  • Actelion

  • Bellerophon

  • Corbus Pharmaceuticals

And Many Others

Emerging and Marketed Pulmonary Sarcoidosis Therapies Covered in the Report Include:

  • CMK 389: Novartis

  • ATYR1923: aTyr Pharma

  • Selexipag: Actelion

  • Combination product: iNO or inhaled nitric oxide: Bellerophon

And Many More

Get an in-depth Assessment of the Emerging Therapies and Pulmonary Sarcoidosis Companies Actively Working in the Market @ 


Table of Content

1. Report Introduction

2. Executive Summary

3. Pulmonary Sarcoidosis Current Treatment Patterns

4. Pulmonary Sarcoidosis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Pulmonary Sarcoidosis Late-Stage Products (Phase-III)

7. Pulmonary Sarcoidosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pulmonary Sarcoidosis Discontinued Products

13. Pulmonary Sarcoidosis Product Profiles

14. Pulmonary Sarcoidosis Companies

15. Pulmonary Sarcoidosis Drugs

16. Dormant and Discontinued Products

17. Pulmonary Sarcoidosis Unmet Needs

18. Pulmonary Sarcoidosis Future Perspectives

19. Pulmonary Sarcoidosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 


Other Trending Healthcare Reports By DelveInsight

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

"Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted Chimeric Antigen Receptor (CAR) T-Cell Therapy market size and share analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.